- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.04.2025 | 822 | Xetra Newsboard | Das Instrument 2NH ES0105043006 NATURHOUSE HEALTH EO-,05 EQUITY wird cum Kapitalmassnahme gehandelt am 02.04.2025 und ex Kapitalmassnahme am 03.04.2025 The instrument 2NH ES0105043006 NATURHOUSE HEALTH... ► Artikel lesen | |
| SPRINT BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 08.01. | Sprint Bioscience AB: Sprint Biosciences upcoming activities | 116 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) summarizes below the company's upcoming meetings with potential partners and investors during the spring of 2025. In addition, the company will present at international scientific... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | - | - | Palatin Technologies, Inc.: Palatin Announces 1-for-50 Reverse Stock Split | PRINCETON, N.J., Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split ("Reverse Stock Split") of its... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,460 | -12,77 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 57,38 | -0,24 % | Halozyme Therapeutics, Inc.: Halozyme Raises 2025 Financial Guidance Ranges And Reports Strong Second Quarter 2025 Results | Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million
Net Income Increased 77% YOY to $165 million; Adjusted EBITDA... ► Artikel lesen | |
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| ABCELLERA BIOLOGICS | 3,941 | +0,56 % | AbCellera Biologics stock rating maintained at Hold by Benchmark | ||
| GLOW LIFETECH | 0,026 | 0,00 % | Glow Lifetech Corp.: Glow Commissions New Automated Bottling Line Supporting Scale-Up and Launches CBG-Based Product in Ontario | Toronto, Ontario--(Newsfile Corp. - July 15, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide a commercial update highlighting continued... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 244,90 | +0,37 % | Disruption! Ab jetzt wird alles anders: BioNxt Solutions, BioNTech, Bio-Rad Laboratories | Der Ausbruch der Corona-Pandemie hat vieles verändert. Frei nach dem Motto "Einfach mal machen" setzten Unternehmen wie BioNTech auf die mRNA-Technologie. Der Erfolg inklusive Milliardenumsätzen folgte... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices, Inc. - 15-12G, Securities registration termination | ||
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd.: BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update | - Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 1,330 | -5,67 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., Aug. 7, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals, Inc.: Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS) | Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10-million-patient marketAcquisition advances Paratek's vision... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 1,890 | -3,08 % | Minerva Neurosciences, Inc: Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results | FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Evaluation of strategic alternatives
BURLINGTON, Mass., Aug. 14, 2025(Nasdaq:... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,395 | -2,81 % | Applied Therapeutics Reports Second Quarter 2025 Financial Results | - CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs: Nasdaq-Rüge wegen Unterschreitung des Mindestkurses | ||
| OVID THERAPEUTICS | 0,760 | -7,88 % | Ovid Therapeutics GAAP EPS of -$0.06, revenue of $6.3M |
SPRINT BIOSCIENCE AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,001 (-1,81 %) liegt der Kurs bei 0,033 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPRINT BIOSCIENCE AB finden Sie auf Wallstreet Online.